Payment overview · 2025
General Payments
$394.18
18 reported records · 12 companies
Healthcare provider profile · identity verified
Nathan J Wright, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TEXARKANA, TX · NPI 1093796534
Verified facts
What the public records show
CMS Open Payments records show Nathan J Wright, M.D. received $394.18 in general payments during 2025 across 18 reported records.
Corcept Therapeutics accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $77.92 | 19.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $64.19 | 16.3% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $43.58 | 11.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.93 | 10.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.91 | 8.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.55 | 7.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.40 | 5.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.08 | 5.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.85 | 5.0% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $14.86 | 3.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.57 | 3.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.34 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $394.18 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $77.92 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $64.19 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $43.58 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.93 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 200 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 152 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
90 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
200 | 76 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 827 | 238 |
| Atorvastatin Calcium | Atorvastatin Calcium | 791 | 268 |
| Amlodipine Besylate | Amlodipine Besylate | 682 | 216 |
| Losartan Potassium | Losartan Potassium | 643 | 216 |
| Pantoprazole Sodium | Pantoprazole Sodium | 620 | 219 |
| Potassium Chloride | Potassium Chloride | 585 | 236 |
| Lisinopril | Lisinopril | 509 | 153 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 486 | 160 |
| Gabapentin | Gabapentin | 472 | 182 |
| Carvedilol | Carvedilol | 417 | 140 |
| Furosemide | Furosemide | 394 | 160 |
| Tramadol Hcl | Tramadol Hcl | 371 | 93 |
| Simvastatin | Simvastatin | 356 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 344 | 105 |
| Omeprazole | Omeprazole | 309 | 97 |
| Metoprolol Tartrate | Metoprolol Tartrate | 269 | 99 |
| Sertraline Hcl | Sertraline Hcl | 253 | 93 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 83 |
| Glimepiride | Glimepiride | 215 | 76 |
| Eliquis | Apixaban | 200 | 76 |
| Lorazepam | Lorazepam | 194 | 44 |
| Metformin Hcl | Metformin Hcl | 188 | 74 |
| Metformin Hcl Er | Metformin Hcl | 174 | 50 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 167 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 57 |
| Meloxicam | Meloxicam | 158 | 57 |
| Ozempic | Semaglutide | 152 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 151 | 58 |
| Paroxetine Hcl | Paroxetine Hcl | 138 | 49 |
| Ondansetron Odt | Ondansetron | 133 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 44 |
| Alprazolam | Alprazolam | 130 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 38 |
| Trazodone Hcl | Trazodone Hcl | 130 | 51 |
| Clonazepam | Clonazepam | 129 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 123 | 43 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 117 | 100 |
| Donepezil Hcl | Donepezil Hcl | 112 | 40 |
| Spironolactone | Spironolactone | 106 | 39 |
| Fenofibrate | Fenofibrate Nanocrystallized | 105 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 34 |
| Methocarbamol | Methocarbamol | 103 | 41 |
| Montelukast Sodium | Montelukast Sodium | 103 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 38 |
| Synthroid | Levothyroxine Sodium | 90 | 25 |
| Clonidine Hcl | Clonidine Hcl | 86 | 38 |
| Torsemide | Torsemide | 86 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 20 |
| Celecoxib | Celecoxib | 85 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 38 |
| Finasteride | Finasteride | 81 | 32 |
| Propranolol Hcl | Propranolol Hcl | 81 | 30 |
| Azithromycin | Azithromycin | 79 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 35 |
| Pregabalin | Pregabalin | 79 | 30 |
| Temazepam | Temazepam | 79 | 12 |
| Allopurinol | Allopurinol | 78 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 35 |
| Alendronate Sodium | Alendronate Sodium | 73 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 31 |
| Prednisone | Prednisone | 69 | 56 |
| Atenolol | Atenolol | 68 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | 23 |
| Farxiga | Dapagliflozin Propanediol | 60 | 26 |
| Januvia | Sitagliptin Phosphate | 60 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | 14 |
| Nifedipine Er | Nifedipine | 53 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 16 |
| Memantine Hcl | Memantine Hcl | 50 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 50 | 23 |
| Famotidine | Famotidine | 49 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 14 |
| Diazepam | Diazepam | 47 | 11 |
| Ezetimibe | Ezetimibe | 47 | 18 |
| Trulicity | Dulaglutide | 47 | 14 |
| Midodrine Hcl | Midodrine Hcl | 45 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 16 |
| Ramipril | Ramipril | 44 | 16 |
| Mometasone Furoate | Mometasone Furoate | 43 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 14 |
| Lansoprazole | Lansoprazole | 41 | 11 |
| Baclofen | Baclofen | 40 | 18 |
| Zaleplon | Zaleplon | 40 | 15 |
| Novolog Flexpen | Insulin Aspart | 39 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Valsartan | Valsartan | 38 | 13 |
| Sucralfate | Sucralfate | 37 | 18 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | 19 |
| Bupropion Xl | Bupropion Hcl | 35 | 14 |
| Buspirone Hcl | Buspirone Hcl | 34 | 15 |
| Clonidine | Clonidine | 34 | 13 |
| Levetiracetam | Levetiracetam | 34 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 12 |
| Klor-Con M20 | Potassium Chloride | 32 | 13 |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 32 | 13 |
| Edarbi | Azilsartan Medoxomil | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | 12 |
| Irbesartan | Irbesartan | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 18 |
| Valacyclovir | Valacyclovir Hcl | 24 | 11 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 23 |
| Linzess | Linaclotide | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | 11 |
| Meclizine Hcl | Meclizine Hcl | 22 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Nystatin | Nystatin | 19 | 14 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 16 |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 16 |
| Olanzapine | Olanzapine | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 13 |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $394.18 · 18 records | Corcept Therapeutics | Cologuard Collection Kit, ELIQUIS, EVENITY, INSPIRE, Korlym, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, WATCHMAN FLX, Wegovy, t:slim X2 Insulin Pump with Control-IQ | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error